{
    "ticker": "ZPTA",
    "name": "Zynerba Pharmaceuticals, Inc.",
    "description": "Zynerba Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing innovative therapies for patients with rare and debilitating neuropsychological conditions. Founded in 2007, Zynerba is at the forefront of cannabinoid-based treatments, aiming to provide new options for patients suffering from conditions such as autism spectrum disorder and fragile X syndrome. The company utilizes its proprietary transdermal delivery technology to create non-invasive, cannabinoid-infused formulations that are designed to improve patient adherence and optimize therapeutic outcomes. Zynerba's lead product candidate, Zygel, is a transdermal gel formulation of cannabidiol (CBD) that is being investigated for its efficacy and safety in treating behavioral symptoms associated with autism. The company's commitment to scientific rigor and patient-centric solutions is evident in its comprehensive clinical trials and research initiatives. Zynerba is dedicated to advancing the field of cannabinoid medicine, working closely with regulatory bodies to ensure that its products meet the highest standards of safety and efficacy. As the landscape of cannabinoid therapies evolves, Zynerba is poised to play a significant role in transforming treatment paradigms for patients with unmet medical needs.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Devon, Pennsylvania, USA",
    "founded": "2007",
    "website": "https://www.zynerba.com",
    "ceo": "Armando Anido",
    "social_media": {
        "twitter": "https://twitter.com/ZynerbaPharma",
        "linkedin": "https://www.linkedin.com/company/zynerba-pharmaceuticals/"
    },
    "investor_relations": "https://investors.zynerba.com",
    "key_executives": [
        {
            "name": "Armando Anido",
            "position": "CEO"
        },
        {
            "name": "William D. McDade",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cannabinoid Therapies",
            "products": [
                "Zygel"
            ]
        }
    ],
    "seo": {
        "meta_title": "Zynerba Pharmaceuticals, Inc. | Innovative Cannabinoid Therapies",
        "meta_description": "Explore Zynerba Pharmaceuticals, Inc., a leader in cannabinoid-based therapies for rare neuropsychological conditions. Discover their innovative products and research.",
        "keywords": [
            "Zynerba",
            "Cannabinoid Therapies",
            "Zygel",
            "Autism Treatment",
            "Pharmaceuticals",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What is Zynerba Pharmaceuticals known for?",
            "answer": "Zynerba Pharmaceuticals is known for developing cannabinoid-based therapies for neuropsychological conditions."
        },
        {
            "question": "Who is the CEO of Zynerba Pharmaceuticals?",
            "answer": "Armando Anido is the CEO of Zynerba Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Zynerba Pharmaceuticals headquartered?",
            "answer": "Zynerba Pharmaceuticals is headquartered in Devon, Pennsylvania, USA."
        },
        {
            "question": "What is Zynerba's lead product candidate?",
            "answer": "Zynerba's lead product candidate is Zygel, a transdermal gel formulation of cannabidiol (CBD)."
        },
        {
            "question": "When was Zynerba Pharmaceuticals founded?",
            "answer": "Zynerba Pharmaceuticals was founded in 2007."
        }
    ],
    "competitors": [
        "GWPH",
        "CRON",
        "APHA",
        "TLRY"
    ],
    "related_stocks": [
        "VRTX",
        "AMGN",
        "REGN",
        "GILD"
    ]
}